TBCRC 031: Randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with her2-negative breast cancer (the inform trial)

Nadine Tung, Banu Arun, Michele R. Hacker, Erin Hofstatter, Deborah L. Toppmeyer, Steven J. Isakoff, Virginia Borges, Robert D. Legare, Claudine Isaacs, Antonio C. Wolff, Paul Kelly Marcom, Erica L. Mayer, Paulina B. Lange, Andrew J. Goss, Colby Jenkins, Ian E. Krop, Eric P. Winer, Stuart J. Schnitt, Judy E. Garber

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Fingerprint

Dive into the research topics of 'TBCRC 031: Randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with her2-negative breast cancer (the inform trial)'. Together they form a unique fingerprint.

Medicine & Life Sciences